Download PDF
CC BY 4.0 · Journal of Health and Allied Sciences NU 2024; 14(01): 038-046
DOI: 10.1055/s-0043-1769903
Review Article

Drug Reprofiling: A Prospective Approach to Battle Chronic Ailments

Natasha Naval Aggarwal 
1   Department of Pharmachemistry, Yenepoya Pharmacy College and Research Center, Yenepoya (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India
,
S.M. Sindhoor 
2   Department of Pharmaceutics, P.A College of Pharmacy, Nadupadav, Montepadav Post, Kairangala, Mangalore, Karnataka, India
,
N. Raghavendra Naveen
3   Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, Mangaluru
,
Buduru Gowthami
4   Department of Pharmaceutics, Annamacharya College of Pharmacy, New Boyanapalli, Rajampet, Andhra Pradesh, India
,
Prajitha Biju
5   Department of Pharmaceutics, Yenepoya Pharmacy College & research Centre, Yenepoya (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India
› Author Affiliations Funding This review did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
› Further Information
Also available at
   Permissions and Reprints

Abstract

The concept of drug “reprofiling” has garnered attention in the recent past post the outbreak of coronavirus disease 2019 when traditional drug discovery seemed to fail. Even though repurposing is called pharma-friendly in terms of monetary relief, clinical trials play an integral role in repurposed nontarget /combination moieties. Nevertheless, when a drug exhibits no returns to the market, an exhaustive study on mechanism of action (MOA) can help for reprofiling of drugs for new indications. However, several papers have claimed that scarcity of resources and data access, and staffing issues, tends to pull down reprofiling of drugs. In contrast to this notion, a total of 155 patented articles to date give a strong base for drug repurposing. In the present review, a scientific prospection of reprofiled antifungal and antiviral agents for the past decade was made using the PubMed database wherein a total of 410 and 768 publications have resulted respectively. The authors have attempted to focus their attention to repurposing antifungal drugs for chronic ailments and infectious diseases by understanding their MOA.

For example, antifungal azoles, which work by blocking ergosterol synthesis, can be repurposed as they inhibit histone deacetylase as well significantly decrease the production of cytokines and modulate the inflammatory pathways used by cancer cells.

Hence, we believe that the mentioned Food and Drug Administration-approved drug candidates can be utilized to treat nontarget diseases, notably rare/neglected diseases as well as chronic illnesses and the more recent viral infections that are spreading globally.

Keywords

antibiotic - FDA-approved - tumors

Statement of Institutional Review Board Approval and/or Statement of Conforming to the Declaration of Helsinki

Not Applicable.


Authors' Contributions

P.B. was involved in hypothesis of the subject and article writing, preparing the final draft Natasha. N.A. was involved in article writing, hypothesis of the subject, and article correction. S.S.M. contributed to hypothesis of the subject and article correction. N.R.N. and B.G. helped in article writing. All authors have read and approved the manuscript.




Publication History

Article published online:
20 June 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rajagopal K, Byran G, Jupudi S, Vadivelan R. Activity of phytochemical constituents of black pepper, ginger, and garlic against coronavirus (COVID-19): an in silico approach. Int J Heal Allied Sci 2020; 9: 43-50
    CrossrefGoogle Scholar
  • 2 Michael ML, Moses JA. Characterization of silver nanoparticles synthesized using Ocimum Basilicum seed extract. Lett Appl NanoBio Science 2021; 11: 3411-3420
    CrossrefGoogle Scholar
  • 3 Dave K. Bioengineering a cadmium sensing green fluorescent protein based whole-cell biosensor from Pseudomonas aeruginosa. Proc. Int. 2020; 2: 2032-2043
    Google Scholar
  • 4 Eastman RT, Roth JS, Brimacombe KR. et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020; 6: 672-683
    CrossrefPubMedGoogle Scholar
  • 5 Mulangu S, Dodd LE, Davey Jr RT. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-2303
    CrossrefPubMedGoogle Scholar
  • 6 Jordan R. et al. Broad-spectrum investigational agent GS-5734 for the treatment of Ebola, MERS coronavirus and other pathogenic viral infections with high outbreak potential. Open Forum Infect Dis 2017; 4 (Suppl. 01) S737
    CrossrefGoogle Scholar
  • 7 Koch S, Pong W. First up for COVID-19: nearly 30 clinical readouts before end of April. Accessed March 21, 2023 at: https://www.biocentury.com/article/304658/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months
    Google Scholar
  • 8 Riva L. et al. A large-scale drug repositioning survey for SARS-CoV-2 antivirals. bioRxiv 2020 2020.04.16.044016
    PubMedGoogle Scholar
  • 9 Van der Jeught K, Xu H, Li Y, Lu X, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24: 3834-3848
    CrossrefPubMedGoogle Scholar
  • 10 Pushpakom S, Iorio F, Eyers P. et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18: 41-58
    CrossrefPubMedGoogle Scholar
  • 11 Napolitano F, Zhao Y, Moreira VM. et al. Drug repositioning: a machine-learning approach through data integration. J Cheminform 2013; 5 (01) 30
    CrossrefPubMedGoogle Scholar
  • 12 Pirone L, Gatto AD, Gaetano SD. et al. A multi-targeting approach to fight SARS-CoV-2 attachment. Front Mol Biosci 2020; 7: 1-5
    CrossrefPubMedGoogle Scholar
  • 13 Vincent MJ, Bergeron E, Benjannet S. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 69: 2-10
    Google Scholar
  • 14 Sumudu P, Leelananda SP. Computational methods in drug discovery. Beilstein J Org Chem 2016; 12: 2694-2718
    CrossrefPubMedGoogle Scholar
  • 15 Zhu N. A novel coronavirus from patients with pneumonia in China. N Engl J Med 2020; 382: 727-733
    CrossrefPubMedGoogle Scholar
  • 16 Zhavoronkov A. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. Mol Pharm 2018; 15: 4311-4313
    CrossrefPubMedGoogle Scholar
  • 17 Shi J, Zhou L, Huang HS. et al. Repurposing oxiconazole against colorectal cancer via PRDX2-mediated autophagy arrest. Int J Biol Sci 2022; 18: 3747-3761
    CrossrefPubMedGoogle Scholar
  • 18 Islam MM, Naveen NR, Anitha P. et al. The race to replace PDE5i: recent advances and interventions to treat or manage erectile dysfunction: evidence from patent landscape (2016–2021). J Clin Med 2022; 11: 3140
    CrossrefPubMedGoogle Scholar
  • 19 A Study in Patients with Erectile Dysfunction—Full Text View. Accessed March 21, 2023 at: https://clinicaltrials.gov/ct2/show/NCT01122264?cond=erectile+dysfunction&phase=3&draw=5&rank=1
    Google Scholar
  • 20 Custodio MM, Sparks J, Long TE. Disulfiram: A repurposed drug in preclinical and clinical development for the treatment of infectious diseases. Antiinfect Agents 2022; 20 (03) e040122199856
    Google Scholar
  • 21 Weng N, Qin S, Liu J. et al. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Acta Pharm Sin B 2022; 12: 3085-3102
    CrossrefPubMedGoogle Scholar
  • 22 Prado-Carrillo O, Arenas-Ramírez A, Llaguno-Munive M. et al. Ketoconazole reverses imatinib resistance in human chronic myelogenous leukemia K562 cells. Int J Mol Sci 2022; 23: 7715
    CrossrefPubMedGoogle Scholar
  • 23 Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes 2013; 4: 66-71
    CrossrefPubMedGoogle Scholar
  • 24 Gupta Y, Goicoechea S, Romero JG. et al. Repurposing Lansoprazole and Posaconazole to treat leishmaniasis: integration of in vitro testing, pharmacological corroboration, and mechanisms of action. Yao Wu Shi Pin Fen Xi 2022; 30 (01) 128-149
    Google Scholar
  • 25 DeSarno AE, Parcell BJ, Coote PJ. Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae. Pathog Dis 2020; 78 (09) ftaa063
    CrossrefPubMedGoogle Scholar
  • 26 A phase I trial of nelfinavir (viracept) in adults with solid tumors. Accessed March 21, 2023 at: https://clinicaltrials.gov/ct2/show/record/NCT01445106?term=anti+viral&cond=drug+repurposing&draw=2&rank=2
  • 27 Gewili N, Abdelghany AM, Mekhaimer M, Oraby A. Synthesis and optical properties of chitosan/polypyrrole composite for biological applications. Lett. Appl NanoBioScience 2021; 10: 2742-2749
    CrossrefGoogle Scholar
  • 28 Banerjee A, Sarkar A, Acharya K, Chakraborty N. Nanotechnology: an emerging hope in crop improvement. Lett Appl NanoBioScience 2021; 10: 2784-2803
    CrossrefGoogle Scholar
  • 29 Novindriani D, Novindriana D, Wijianto B, Andrie M. Studies on the Sedative Effect of Mitragyna Speciosa Korth. as an Endemic Plant in West Borneo, Indonesia. Lett. Appl . NanoBioScience 2021; 11: 3344-3349
    Google Scholar
  • 30 Bakr A. Purification and characterization of milk clotting enzyme from edible mushroom (Pleurotus Florida). Lett. Appl . NanoBioScience 2021; 11: 3362-3373
    Google Scholar
  • 31 Gameiro GR, Sinkunas V, Liguori GR, Auler-Júnior JOC. Precision medicine: changing the way we think about healthcare. Clinics (São Paulo) 2018; 73: e723
    CrossrefPubMedGoogle Scholar
  • 32 Odekunle FF. Association of PIK3CA and PTEN Genetic Alterations with Cervical Cancer Mortality and Tumor Recurrence (Doctoral dissertation, Rutgers The State University of New Jersey, Rutgers School of Health Professions)
  • 33 Xue HJ, Li Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci 2018; 14: 1232-1244
    CrossrefPubMedGoogle Scholar
  • 34 Schein CH. Repurposing approved drugs on the pathway to novel therapies. Med Res Rev 2020; 40: 586-605
    CrossrefPubMedGoogle Scholar
  • 35 Farhana N. Meticulous Endorsement of Black Seed and Jambolana: A Scientific. Herbs and Spices: New Processing Technologies. 2021 Dec 1:165.
  • 36 Barratt MJ, Frail DE. Drug repositioning: Bringing new life to shelved assets and existing drugs. Hoboken, New Jersey, United States: John Wiley & Sons; 2012. 01. 65-88
    CrossrefGoogle Scholar
  • 37 Oprea TI. Drug repurposing funding projects. Drug Discov Today Ther Strateg 2011; 8: 61-69
    PubMedGoogle Scholar
  • 38 Cusinato J, Cau Y, Calvani AM, Mori M. Repurposing drugs for the management of COVID-19. Expert Opin Ther Pat 2021; 31: 295-307
    CrossrefPubMedGoogle Scholar
  • 39 Schenone M, Wagner BKP, Clemons A, Program B. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 2017; 9 (04) 232-240
    CrossrefPubMedGoogle Scholar
  • 40 Kim JH. Antifungal drug repurposing. Antibiotics (Basel) 2020; 9: 1-29
    Google Scholar
  • 41 Pavlopoulos GA, Wegener AL, Schneider R. A survey of visualization tools for biological network analysis. BioData Min 2008; 1: 1-11
    CrossrefPubMedGoogle Scholar
  • 42 Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012; 2012: 713687
    CrossrefPubMedGoogle Scholar
  • 43 Dixit H, Sharma A, Chandel V, Porte SM. Ayurvedic methods of diagnosis and management of Dadru Kushta W. S. R. to fungal infection. Int J Health Sci Res 2020; 10: 114-120
    Google Scholar
  • 44 Garg A, Sharma GS, Goyal AK, Ghosh G, Si SC, Rath G. Recent advances in topical carriers of anti-fungal agents. Heliyon 2020; 6: e04663
    CrossrefPubMedGoogle Scholar
  • 45 Kim S. PubChem substance and compound databases. Nucleic Acids Res 2016; 44: 1202-1213
    CrossrefPubMedGoogle Scholar